A Study to Evaluate ICP-022 in Patients With CLL/ SLL

Key facts

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.

Principal Investigator

Jianyong Li, MD

The First Affiliated Hospital with Nanjing Medical University

Intervention

ICP-022(drug)

Enrollment

100 enrolled

Eligibility

18 years · All sexes

Timeline

2018 – 2022

Study locations (25)

• Anhui Province Cancer Hospital, Hefei, Anhui, China
• Peking University People's Hospital, Beijing, Beijing Municipality, China
• Peking University Third Hospital, Beijing, Beijing Municipality, China
• Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
• Fujian Medical University Union Hospital, Fuzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
• Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
• Guangzhou First People's Hospital, Guangzhou, Guangdong, China
• The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
• Henan Provincial People's Hospital, Zhengzhou, Henan, China
• Henan Tumor Hospital, Zhengzhou, Henan, China
• Wuhan Union Hospital, Wuhan, Hubei, China
• Tongji Hospital, Wuhan, Hubei, China
• Jiangsu Province Hospital, Nanjing, Jiangsu, China
• Jilin Cancer Hospital, Changchun, Jilin, China
• +10 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07194980
  Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Fred Hutchinson Cancer Center
• RECRUITINGEARLY PHASE1NCT07428707
  Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
  National Heart, Lung, and Blood Institute (NHLBI)
• RECRUITINGPHASE4NCT07218341
  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Eli Lilly and Company
• RECRUITINGPHASE1NCT06859008
  Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07271667
  A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
  Curis, Inc.
• RECRUITINGPHASE2NCT07014917
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
  Zulfa Omer
• RECRUITINGPHASE2NCT06958705
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
  The First Affiliated Hospital with Nanjing Medical University
• RECRUITINGPHASE1, PHASE2NCT07052695
  Mosunetuzumab for CLL MRD Clearance
  Inhye Ahn

See all trials for B-cell chronic lymphocytic leukemia →